KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Acadia Pharmaceuticals (ACAD) Equity Average (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 15 years of Equity Average data on record, last reported at $1.1 billion in Q4 2025.

  • For Q4 2025, Equity Average rose 63.72% year-over-year to $1.1 billion; the TTM value through Dec 2025 reached $1.1 billion, up 63.72%, while the annual FY2025 figure was $980.1 million, 68.32% up from the prior year.
  • Equity Average reached $1.1 billion in Q4 2025 per ACAD's latest filing, up from $869.8 million in the prior quarter.
  • Across five years, Equity Average topped out at $1.1 billion in Q4 2025 and bottomed at $379.0 million in Q3 2023.
  • Average Equity Average over 5 years is $562.3 million, with a median of $519.9 million recorded in 2022.
  • Peak YoY movement for Equity Average: dropped 25.43% in 2022, then surged 67.23% in 2025.
  • A 5-year view of Equity Average shows it stood at $553.9 million in 2021, then decreased by 25.43% to $413.0 million in 2022, then decreased by 3.89% to $397.0 million in 2023, then surged by 65.0% to $655.0 million in 2024, then surged by 63.72% to $1.1 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Average were $1.1 billion in Q4 2025, $869.8 million in Q3 2025, and $793.8 million in Q2 2025.